Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
Maja Di Rocco, Eduardo Forleo-Neto, Robert Pignolo, Richard Keen, Philippe Orcel, Thomas Funck-Brentano, Christian Roux, Sami Kolta, Annalisa Madeo, Judith S Bubbear, Jacek Tabarkiewicz, Małgorzata Szczepanek, Javier Bachiller-Corral, Angela M Cheung, Kathryn M Dahir, Esmée Botman, Pieter G Raijmakers, Mona Al Mukaddam, Lianne Tile, Cynthia Portal-Celhay, Neena Sarkar, Peijie Hou, Bret Musser, Anita Boyapati, Kusha Mohammadi, Scott Mellis, Andrew J. Rankin, Aris N. Economides, Dinko Gonzalez Trotter, Gary Herman, Sarah J. O’Meara, Richard DelGizzi, David M. Weinreich, George D. Yancopolous, E. Marelise W. Eekhoff, Frederick S. Kaplan the LUMINA-1 Investigators
doi: https://doi.org/10.1101/2023.01.11.23284254
Maja Di Rocco
1Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy
MD, PhDEduardo Forleo-Neto
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MDRobert Pignolo
3Department of Medicine, Mayo Clinic, Rochester, MN, USA
MD, PhDRichard Keen
4Centre for Metabolic Bone Disease Royal National Orthopaedic Hospital NHS Trust, London, UK
PhD, FRCPPhilippe Orcel
5Department of Rheumatology-DMU Locomotion, Assistance Publique - Hôpitaux de Paris, Paris, France
6INSERM Université Paris Cité, Paris, France
MD, PhDThomas Funck-Brentano
5Department of Rheumatology-DMU Locomotion, Assistance Publique - Hôpitaux de Paris, Paris, France
6INSERM Université Paris Cité, Paris, France
MD, PhDChristian Roux
7Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
MD, PhDSami Kolta
7Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
MDAnnalisa Madeo
1Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy
MDJudith S Bubbear
4Centre for Metabolic Bone Disease Royal National Orthopaedic Hospital NHS Trust, London, UK
MD, FRCPJacek Tabarkiewicz
8Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów University, Rzeszów, Podkarpackie, Poland
MD, PhDMałgorzata Szczepanek
8Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów University, Rzeszów, Podkarpackie, Poland
MD, PhDJavier Bachiller-Corral
9Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
MDAngela M Cheung
10University Health Network, University of Toronto, Toronto, ON, Canada
MD, PhDKathryn M Dahir
11Vanderbilt University Medical Center, Program for Metabolic Bone Disorders, Nashville, TN, USA
MDEsmée Botman
12Department of Internal Medicine Section of Endocrinology, Amsterdam UMC, Vrije Universiteit, Amsterdam Bone Center, Amsterdam, The Netherlands
MD, PhDPieter G Raijmakers
13Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands
MD, PhDMona Al Mukaddam
14Departments of Orthopaedics, Medicine and the Center for Research in FOP & Related Disorders, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
MDLianne Tile
10University Health Network, University of Toronto, Toronto, ON, Canada
MDCynthia Portal-Celhay
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MD, PhDNeena Sarkar
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDPeijie Hou
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDBret Musser
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDAnita Boyapati
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDKusha Mohammadi
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDScott Mellis
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MD, PhDAndrew J. Rankin
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDAris N. Economides
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDDinko Gonzalez Trotter
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDGary Herman
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MDSarah J. O’Meara
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
PhDRichard DelGizzi
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MSDavid M. Weinreich
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MDGeorge D. Yancopolous
2Regeneron Pharmaceuticals, Tarrytown, NY, USA
MD, PhDE. Marelise W. Eekhoff
12Department of Internal Medicine Section of Endocrinology, Amsterdam UMC, Vrije Universiteit, Amsterdam Bone Center, Amsterdam, The Netherlands
MD, PhDFrederick S. Kaplan
14Departments of Orthopaedics, Medicine and the Center for Research in FOP & Related Disorders, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
MD
Article usage
Posted January 13, 2023.
Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
Maja Di Rocco, Eduardo Forleo-Neto, Robert Pignolo, Richard Keen, Philippe Orcel, Thomas Funck-Brentano, Christian Roux, Sami Kolta, Annalisa Madeo, Judith S Bubbear, Jacek Tabarkiewicz, Małgorzata Szczepanek, Javier Bachiller-Corral, Angela M Cheung, Kathryn M Dahir, Esmée Botman, Pieter G Raijmakers, Mona Al Mukaddam, Lianne Tile, Cynthia Portal-Celhay, Neena Sarkar, Peijie Hou, Bret Musser, Anita Boyapati, Kusha Mohammadi, Scott Mellis, Andrew J. Rankin, Aris N. Economides, Dinko Gonzalez Trotter, Gary Herman, Sarah J. O’Meara, Richard DelGizzi, David M. Weinreich, George D. Yancopolous, E. Marelise W. Eekhoff, Frederick S. Kaplan
medRxiv 2023.01.11.23284254; doi: https://doi.org/10.1101/2023.01.11.23284254
Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
Maja Di Rocco, Eduardo Forleo-Neto, Robert Pignolo, Richard Keen, Philippe Orcel, Thomas Funck-Brentano, Christian Roux, Sami Kolta, Annalisa Madeo, Judith S Bubbear, Jacek Tabarkiewicz, Małgorzata Szczepanek, Javier Bachiller-Corral, Angela M Cheung, Kathryn M Dahir, Esmée Botman, Pieter G Raijmakers, Mona Al Mukaddam, Lianne Tile, Cynthia Portal-Celhay, Neena Sarkar, Peijie Hou, Bret Musser, Anita Boyapati, Kusha Mohammadi, Scott Mellis, Andrew J. Rankin, Aris N. Economides, Dinko Gonzalez Trotter, Gary Herman, Sarah J. O’Meara, Richard DelGizzi, David M. Weinreich, George D. Yancopolous, E. Marelise W. Eekhoff, Frederick S. Kaplan
medRxiv 2023.01.11.23284254; doi: https://doi.org/10.1101/2023.01.11.23284254
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2960)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12768)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4604)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2935)
- Health Policy (1069)
- Hematology (390)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (471)
- Neurology (4383)
- Nursing (237)
- Nutrition (641)
- Oncology (2282)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1198)
- Primary Care Research (499)
- Public and Global Health (6967)
- Radiology and Imaging (1537)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)